Group 1 - Berry Genomics (000710.SZ) released its 2024 annual report on April 25, 2025, indicating that as of April 24, 2025, 44 institutional investors disclosed holding A-shares, totaling 79.7934 million shares, which accounts for 22.57% of the total share capital [1] - The top ten institutional investors include Chengdu Tianxing Instrument (Group) Co., Ltd., Hongling Siqi (Zhuhai) M&A Equity Investment Enterprise (Limited Partnership), and others, with a combined holding ratio of 22.43%, reflecting a decrease of 1.55 percentage points compared to the previous quarter [1] - In the public fund sector, 37 new public funds were disclosed this period compared to the previous quarter, including funds such as Huatai-PB CSI Precision Medicine Index (LOF) A and Medical Device ETF [1] Group 2 - Foreign institutional investors that did not disclose holdings this period include MORGAN STANLEY & CO. INTERNATIONAL PLC, BARCLAYS BANK PLC, and J.P. Morgan Securities PLC - proprietary funds [2]

Core Viewpoint - The company focuses on food safety rapid testing and animal diagnostics, aiming to expand its market presence both domestically and internationally through innovative products and strategic partnerships [5][10][19]. Company Overview - The company specializes in food safety rapid testing and is expanding into animal diagnostics, providing comprehensive testing solutions across various stages of the food supply chain [5][10]. - The main products include rapid test reagents, testing instruments, and related services, ensuring food safety from production to retail [6][8]. Business Segments Food Safety Rapid Testing - The company offers a range of rapid test products, including immunochromatographic test strips and ELISA kits, applicable to various food categories such as dairy, meat, and vegetables [6][7]. - The company has developed a high-throughput multi-residue testing card for pesticide residues, capable of detecting 16 types of pesticides simultaneously within 9 minutes [8][22]. Animal Diagnostics - The animal diagnostics segment is managed by a wholly-owned subsidiary, focusing on rapid testing for livestock and companion animals, including pregnancy tests and pathogen detection [10][24]. - The company aims to leverage its existing customer base in food safety to enhance sales in animal diagnostics, particularly in markets with significant livestock populations [24]. Market Strategy - The company is deepening its international strategy, targeting untapped markets in dairy product testing and other areas, with a focus on obtaining local certifications and building partnerships [19][20]. - The global market for mycotoxin testing kits is projected to reach $825.7 million by 2028, indicating significant growth potential for the company's products in this area [19]. Regulatory Environment - Increasing domestic regulations on food safety are driving demand for testing services, as companies seek to comply with stricter standards [25]. - The company is positioned to benefit from heightened consumer awareness regarding food safety, leading to increased testing requirements from food producers and retailers [25]. Technological Innovation - The company has developed an automated digital testing platform that enhances testing efficiency and reduces costs for clients, integrating data management and real-time monitoring [26]. - A new chemiluminescence technology platform allows for multi-parameter testing in a single device, streamlining the testing process and improving accuracy [27]. Financial Performance - The company has maintained a stable financial position, with no need for restating previous financial data, indicating consistent operational performance [30]. - The company has received various certifications, reflecting its commitment to quality and innovation in the testing industry [29].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -1.4140 | -0.7500 | -88.53 | 1.7220 | | 每股净资产（元） | 13.03 | 14.82 | -12.08 | 19.04 | | 每股公积金(元) | 12.39 | 12.4 | -0.08 | 14.9 | | 每股未分配利润(元) | -0.15 | 1.25 | -112 | 2.93 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 1.26 | 1.71 | -26.32 | 5.22 | | 净利润(亿元) | -1.57 | -0.84 | -86.9 | 1.59 | | 净资产收益率(%) | -10.05 | -4.93 | -103.85 | 19.82 | 三、分红送配方案情况 不分配不转增 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 1356.09万股，累计占 ...

金十数据4月24日讯，睿昂基因发布一季报，营业收入为5473.80万元，同比下降14.72%；归属于上市公 司股东的净利润为335.50万元，同比增长529.26%。净利润增长主要系子公司长春技特收到流式细胞相 关研究项目政府补助尾款180万；收回前期单项计提的一笔应收坏账247.63万元。 睿昂基因：一季度净利润同比增长529.26% ...

Core Viewpoint - The major industry ETFs in the US stock market showed mixed performance, with semiconductor and internet stock index ETFs leading the gains [1]. Group 1: Semiconductor and Internet Stocks - The semiconductor ETF (SMH) increased by 4.56 to 203.47, representing a rise of 2.29% with a trading volume of 678,200 shares and a total value of 24.05 billion [1]. - The internet stock index ETF (FDN) rose by 3.47 to 222.01, marking a gain of 1.59% with a trading volume of 8,124 shares and a total value of 147.41 billion [1]. Group 2: Other Technology and Sector ETFs - The technology sector ETF (XLK) saw an increase of 2.88 to 200.92, which is a 1.45% rise with a trading volume of 312,500 shares and a total value of 639.04 billion [1]. - The gold ETF (GLD) rose by 2.21 to 305.87, reflecting a 0.73% increase with a trading volume of 1,639,300 shares and a total value of 827.36 billion [1]. - The energy sector ETF (XLE) increased by 0.53 to 81.77, a rise of 0.65% with a trading volume of 776,800 shares and a total value of 204.77 billion [1]. Group 3: Underperforming ETFs - The biotechnology index ETF (IBB) decreased by 0.17 to 121.83, a decline of 0.14% with a trading volume of 67,616 shares and a total value of 96.73 billion [1]. - The regional bank ETF (KRE) fell by 0.10 to 53.45, representing a decrease of 0.18% with a trading volume of 1,204,100 shares and a total value of 44.61 billion [1]. - The financial sector ETF (XLF) declined by 0.15 to 47.56, a drop of 0.32% with a trading volume of 2,697,600 shares and a total value of 529.42 billion [1].

Core Insights - Berry Genomics (000710) reported a revenue of 1.078 billion yuan for 2024, representing a year-on-year decline of 6.36% [1] - The net loss attributable to shareholders was 192 million yuan, compared to a net loss of 427 million yuan in the same period last year [1] - The basic earnings per share were -0.5443 yuan per share [1] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [1]

4月24日，之江生物今日收盘16.17元，下跌1.40%，最新市净率0.82，总市值31.07亿元。 上海之江生物科技股份有限公司主营业务为分子诊断试剂及仪器设备的研发、生产和销售。公司在公共 卫生安全和临床诊断领域为客户提供优质的产品及一站式技术服务,致力于为健康医疗事业做出贡献。 公司的主要产品为分子诊断试剂及仪器设备,是国内感染性疾病分子诊断产品最为齐全的企业之一,已开 发400余种产品,覆盖了绝大多数国家法定传染病,广泛应用于突发公共卫生安全、医学临床诊断、出入境 检验检疫、食品安全等领域,远销全球多个国家和地区。公司获得了'国家技术发明奖二等奖'、'国家火炬 计划产业化示范项目证书'等多项荣誉奖项。 最新一期业绩显示，2024年三季报，公司实现营业收入1.38亿元，同比-32.95%；净利润-13009588.94 元，同比-137.56%，销售毛利率72.40%。 截至2024年三季报，共有3家机构持仓之江生物，其中基金3家，合计持股数129.38万股，持股市值0.22 亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)18之江生物-24.37-24.370.8231.07亿行业平均 ...

智通财经APP讯，中国生物科技服务(08037)发布公告，关于上海银行浦东分行(贷款人)向本公司的间接 非全资附属公司上海隆耀生物科技有限公司(上海隆耀)提供为期一年的银行授信。贷款人同意续订银行 授信，上海隆耀与贷款人订立小企业流动资金借款合同(借款合同)。根据借款合同，贷款人同意向上海 隆耀提供本金最多为人民币400万元的信贷额度，自借款合同日期起为期一年，以供用作一般流动资金 用途。 作为根据借款合同提供信贷额度的代价，本公司及本公司的主席、执行董事兼控股股东刘小林先生(刘 先生)各自订立以贷款人为受益人的普惠及小企业借款保证合同(统称"保证合同")，以无条件及不可撤回 的保证妥为及准时履行借款合同的义务，包括上海隆耀据此支付所有到期及应付款项。实际义务由保证 合同的条款管限。 本公司及刘先生以上海市中小微企业政策性融资担保基金管理中心(借款合同的另一名保证人)(该中心) 为受益人，分别签立《不可撤销信用反担保函》及《个人无限连带责任保证函》(统称"反担保函")，为 该中心提供反担保。根据反担保函，本公司及刘先生为该中心提供无限连带责任反担保。反担保的具体 范围、条款及年期由反担保函管限。 借款合同、保 ...

一条条隧道穿越山间，一个个桥墩拔地而起……"中老铁路"自2023年正式通车运营以来，铺就了促进两 国发展的"黄金通道"，有效推动云南省"走出去"企业向"兴"发展。 优化服务，"中老铁路"搭建进出口"黄金桥梁" 近年来，云南以共建"一带一路"为引领，充分发挥地理优势和资源潜力，不断加强与东南亚国家间的经 济合作。云南税务部门聚焦税费服务提质增效，认真梳理分析"走出去"企业涉税诉求，精准施策、优化 服务，为企业高效"出海"提供助力。 在中国(云南)自由贸易试验区德宏片区沿边产业园区，2024年以来新增注册企业500余家，其中制造业 企业100余家，新能源产业也在稳步布局。园区生产的产品不仅满足了国内市场的需求，还远销到周边 国家，为企业带来丰厚的利润，带动了地方经济发展。 走进云南博瑞生物科技有限公司，自动化提取的水溶生产线和油溶生产线运转繁忙，年产上千吨的产品 不断产出，陆续出口东南亚、欧美等市场。一直以来，云南博瑞生物科技有限公司致力于研发天然健康 产品，成立了专门研发中心，配备新产品研发设备30多台。 为支持鼓励中国"智"造走出国门，确保出口企业足额享受出口退税政策红利，云南税务部门主动走向生 产一线开展宣 ...

Investment Rating - The report assigns a "Buy" rating to the company 康方生物 (9926 HK) with a target price of HKD 115.00, indicating a potential upside of 30.1% from the current price of HKD 88.40 [1][7][13]. Core Insights - The success of the second head-to-head Phase III trial for the drug 依沃西 (Ivosidenib) has validated its competitive advantage in the lung cancer treatment market compared to PD-(L)1 monotherapy. The trial achieved significant benefits in progression-free survival (PFS) [7]. - The company has received approval for its first autoimmune product, 依若奇单抗 (Ilumya), which is expected to generate peak sales of approximately RMB 1 billion due to its advantages over competitors in treating moderate to severe plaque psoriasis [7]. - The revenue forecasts for 2025-2027 have been adjusted upwards by 0-6%, with peak sales estimates for 依沃西 in mainland China and overseas raised to RMB 6.1 billion and USD 5.7 billion, respectively [7]. Financial Overview - Revenue projections for 康方生物 are as follows: RMB 4,095 million in 2025, RMB 6,091 million in 2026, and RMB 8,680 million in 2027, reflecting growth rates of 92.8%, 48.8%, and 42.5% respectively [6][15]. - The net profit is expected to recover from a loss of RMB 446 million in 2024 to RMB 629 million in 2025, and further increase to RMB 1,982 million in 2026 and RMB 3,557 million in 2027 [6][15]. - The company’s market capitalization is approximately HKD 79.17 billion, with a year-to-date stock price increase of 45.63% [4][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is projected to be 112.8x in 2025, decreasing to 35.8x in 2026 and further to 19.9x in 2027, indicating improving profitability [6][8]. - The book value per share is expected to rise from RMB 5.58 in 2023 to RMB 14.58 in 2027, with a corresponding decrease in the price-to-book (P/B) ratio from 14.94x to 5.72x [6][8].